DUBLIN--(BUSINESS WIRE)--The "Pneumococcal Vaccines: Epidemiology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
Pneumococcal Vaccination rates in children are expected to remain steady at approximately 85% in the combined seven major markets (7MM - The US, France, Germany, Italy, Spain, the UK and Japan) by 2028, while vaccination rates in the elderly are expected to slightly increase to only 62% in the combined six major markets (6MM - The US, Germany, Italy, Spain, the UK and Japan) by 2028.
Streptococcus pneumoniae (S. pneumoniae) is a bacterial organism that causes a number of diseases, ranging from serious to mild infections. Symptoms depend on the part of the body that is infected, and range from fever, chills, and difficulty breathing to stiff neck and confusion. Transmission of S. pneumoniae primarily occurs through respiratory droplets. The term invasive pneumococcal disease (IPD) refers to more severe infections in which the bacterium is isolated from normally sterile sites. IPD is most common in high-risk groups, such as young children and the elderly, where the immune system is more vulnerable.
With pediatric pneumococcal vaccination, the primary reason for non-vaccination is vaccine hesitancy. In contrast, with elderly vaccination, the primary reason for non-vaccination is a lack of awareness about the pneumococcal vaccine from both the patient and healthcare professional. While pediatric rates are promising, there is still room for improvement. Addressing vaccine hesitancy requires further investigation and analysis into specific social, behavioral and economic factors that play a role in whether or not an individual gets vaccinated.
Furthermore, to help overcome insufficient doctor-patient communication and knowledge about vaccines, incentives or certifications should be offered to doctors who remain up-to-date on national vaccine guidelines and who are properly trained in vaccine counseling. In the future, continued efforts should focus on carrying out a targeted, actionable, and effective country-specific approach to overcome vaccine hesitancy, increase vaccine awareness, and ultimately reduce invasive pneumococcal disease incidence worldwide.
The latest research report Pneumococcal Vaccines: Epidemiology Forecast to 2028 provides an overview of the risk factors and global trends of pneumococcal vaccines in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). Epidemiologists have utilized comprehensive, country-specific pneumococcal vaccination rate data and IPD diagnosed incidence rate data from nationally representative public health surveillance systems and databases to arrive at a meaningful, in-depth epidemiological analysis and forecast. Moreover, epidemiologists have provided detailed dose- and age-specific pneumococcal vaccination rates that are dependent on the routine immunization requirements of each market within this report.
Reasons to buy
The Pneumococcal Vaccines Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global pneumococcal vaccines market.
- Quantify patient populations in the global pneumococcal vaccines market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for pneumococcal vaccine therapeutics in each of the markets covered.
- Understand magnitude of the pneumococcal vaccines population by dose and age.
Key Topics Covered:
1 Pneumococcal Vaccines: Executive Summary
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.3.1 Pediatric and Elderly Pneumococcal Vaccination Rates
2.3.2 Diagnosed Incidence of Invasive Pneumococcal Disease (Cases per 100,000 Population)
2.4 Forecast Methodology
2.4.2 Sources Not Used
2.4.3 Forecast Assumptions and Methods
2.4.4 Pneumococcal Vaccination Rates in the Pediatric Population
2.4.5 Pneumococcal Vaccination Rates in the Elderly Population
2.4.6 Diagnosed Incident Cases of Invasive Pneumococcal Disease
2.5 Epidemiological Forecast for Pneumococcal Vaccines and Invasive Pneumococcal Disease (2018-2028)
2.5.1 Pneumococcal Vaccinated Pediatric Population
2.5.2 Pneumococcal Vaccinated Elderly Population
2.5.3 Diagnosed Incident Cases of IPD
2.5.4 Age-Specific Diagnosed Incident Cases of IPD
2.6.1 Epidemiological Forecast Insight
2.6.2 Limitations of the Analysis
2.6.3 Strengths of the Analysis
3.2 About the Authors
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy
3.3 About the Author
3.4 Contact Us
For more information about this report visit https://www.researchandmarkets.com/r/nzwpzn